Stifel Financial Corp Has $1.46 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Stifel Financial Corp grew its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 26.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 188,844 shares of the biotechnology company's stock after buying an additional 39,564 shares during the period. Stifel Financial Corp owned 0.38% of REGENXBIO worth $1,460,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in RGNX. GAMMA Investing LLC boosted its holdings in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 2,510 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of REGENXBIO during the fourth quarter worth about $54,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of REGENXBIO during the fourth quarter worth about $79,000. Teacher Retirement System of Texas lifted its stake in shares of REGENXBIO by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 2,088 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new position in shares of REGENXBIO during the fourth quarter worth about $97,000. Hedge funds and other institutional investors own 88.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on RGNX. HC Wainwright cut their price target on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, March 17th. Chardan Capital reiterated a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Thursday, March 20th. Leerink Partners set a $24.00 price target on REGENXBIO in a research note on Tuesday, March 18th. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Finally, Morgan Stanley boosted their price objective on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, REGENXBIO has an average rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Stock Up 6.0%

Shares of RGNX stock traded up $0.45 during mid-day trading on Monday, reaching $7.97. The stock had a trading volume of 483,623 shares, compared to its average volume of 847,995. The firm's 50 day simple moving average is $7.32 and its 200 day simple moving average is $8.00. REGENXBIO Inc. has a one year low of $5.04 and a one year high of $16.85. The firm has a market cap of $399.58 million, a PE ratio of -1.58 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million for the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Sell-side analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.